Metavesco Inc (MVCO): It will certainly be interesting......

Play Episode

6min

Proactive - Interviews for investors

Pantheon Resources provides update on MEGREZ-1 flow testing results

Pantheon Resources Chairman David Hobbs and CEO Max Easley joined Steve Darling from Proactive to share preliminary flow test results from the Megrez-1 well in Alaska. The well is part of a six-interval testing program, and the first interval tested, the Topset 1 (TS1) reservoir, was fracture stimulated across 290 feet between 7,165 and 7,453 feet measured depth (MD). The well produced sustained strong liquid rates for 12 days, exceeding 1,000 barrels per day by the end of the flow-back period. However, no appreciable hydrocarbons were recovered during this initial test. Despite this, Easley noted the data reveals the TS1 reservoir is oil bearing but likely located within a transition zone that contains limited to no mobile oil or gas. Importantly, the technical data gathered from this interval has boosted the company's confidence in the five remaining, shallower intervals still to be tested. These higher zones are believed to hold greater potential for mobile hydrocarbons and increased productivity. TS1 will now be abandoned, and preparations are underway to begin testing the Lower Prince Creek interval. High-pressure pumping equipment is currently being mobilized to the Megrez pad. While the initial result may seem underwhelming at first glance, Pantheon emphasized that it strengthens their geological model and supports the likelihood of commercial success in the intervals yet to be tested. #proactiveinvestors #pantheonresourcesplc #mining #lse #panr #pthrf #OilAndGas #MEGREZ1 #FlowTesting #EnergyExploration #Hydrocarbons #AlaskaOil #OilDrilling #ResourceDevelopment #OilfieldUpdate

Proactive - Interviews for investors

European Green Transition co-founder Cathal Friel outlines growth strategy as he takes chair

European Green Transition PLC (AIM:EGT) founder and non-executive chairman Cathal Friel talked with Proactive's Stephen Gunnion about his formal move into the non-executive chairman role and the company’s strategy going forward. Friel shared how European Green Transition (EGT) aims to build value by acquiring distressed yet revenue-generating assets, a model he has successfully applied with previous companies such as Amryt Pharma and hVIVO. “Our model going forward is to acquire low-priced, distressed, good value assets, bolt them together,” he said, emphasising the need for revenue-generating components or the capacity to make acquisitions profitable from day one. He reflected on EGT’s IPO in April 2024 and his transition from other responsibilities, including his long tenure with hVIVO. With that chapter closed, he now brings more focus to EGT’s growth. Friel confirmed that the company still holds the majority of the £6.5 million raised, having only used a small portion on its rare earth asset in Sweden. Monetising that asset remains a priority. EGT's strategy continues to centre on small teams, tight cost control, and targeting multi-fold returns over a 24-month horizon. “I’ll be very careful of [the shareholders’] cash. It’s like mine,” Friel added. Visit Proactive’s YouTube channel for more interviews. Don’t forget to like this video, subscribe, and turn on notifications so you never miss an update. #CathalFriel #EuropeanGreenTransition #EGT #RareEarths #MergersAndAcquisitions #SmallCapInvesting #GreenEconomy #MiningInvestment #ShareholderValue #hVIVO #AmrytPharma #IPO

Proactive - Interviews for investors

Ananda Develops U.S. presence as lead drug advances to Phase 1 clinical study

Ananda Pharma CEO Melissa Sturgess joined Steve Darling from Proactive to announce the company’s shares have begun trading on the OTCQB market in the United States, a strategic move that expands Ananda’s visibility and access to U.S. investors. The UK-based biopharmaceutical company is focused on developing regulatory-approved cannabinoid medicines for complex and chronic medical conditions. Sturgess emphasized the significance of entering the U.S. market, not only from a capital markets perspective but also as a key future territory for Ananda’s clinical and commercial ambitions. She also highlighted recent progress in the company’s clinical development pipeline, particularly around its lead investigational drug candidate, MRX1. Ananda recently received approval from the Alfred Hospital Human Research Ethics Committee in Australia to initiate a Phase 1 pharmacokinetic study of MRX1. The study will evaluate the safety, tolerability, and pharmacokinetics of two dose levels of the CBD-based drug in a cohort of 20 healthy adult volunteers—10 biological males and 10 biological females—to address known sex differences in CBD metabolism. MRX1 is a high-purity, pharmaceutical-grade cannabidiol (CBD) formulation developed under rigorous quality standards to ensure consistency, safety, and clinical reliability. It is intended for the treatment of chronic inflammatory pain conditions, where current treatment options often fall short in efficacy or come with undesirable side effects. Sturgess noted that this ethics approval marks a critical milestone in the company’s journey toward regulatory approval and commercial readiness. The trial is expected to generate key safety and dosing data to support future Phase 2 studies targeting patients with unmet needs in chronic pain management. #proactiveinvestors #aqse #ana #cbd #otcqb #MRX1 #CBDDrugDevelopment #CannabinoidTherapy #ClinicalTrials #FDAApproval #PharmaNews #BiotechStocks #OTCQB #GWPharma #CBDMedicine #ChronicPainTreat

Proactive - Interviews for investors

Genflow Biosciences adds AI power to gene therapy through Heureka Labs collaboration

Genflow Biosciences PLC (LSE:GENF, OTCQB:GENFF) CEO Dr Eric Leire talked with Proactive about the company’s new strategic partnership with US-based Heureka Labs, a spinoff of Duke University, to enhance its gene therapy research using AI technology. Leire said: “Every biotech in gene therapy should have an AI component. If you don't have that, you miss a critical tool to unlock value for your shareholders.” He stressed the need for a multi-omics approach—genomic, transcriptomic, and proteomic—to better understand gene expression and drug response, which traditional analysis methods struggle to fully capture. The partnership with Heureka Labs, which integrates deep AI and biological expertise, will initially support Genflow’s lead candidate, GF-1002, a SIRT-6 gene therapy targeting MASH (metabolic dysfunction-associated steatohepatitis). AI will help the company analyse complex preclinical data, including insights from nearly 700 mice tested, to understand mechanisms of action and identify likely responders—crucial in discussions with regulators such as the FDA and EMA. Leire also emphasised that the collaboration is scalable across Genflow’s pipeline, helping unlock synergies between programmes in liver, muscle, and eye diseases. For more interviews like this, visit Proactive’s YouTube channel. Don’t forget to give this video a like, subscribe to the channel, and enable notifications for future content. #GenflowBiosciences #GeneTherapy #AIinBiotech #BiotechNews #MASH #SIRT6 #HeurekaLabs #DrugDevelopment #MultiOmics #BiotechPartnership #FDA #EMA #PreclinicalResearch

Followers	77
Posts	19332
Boards Moderated	2
Alias Born	04/16/2019

Volume:	8,930,688
Day Range:	0.00085 - 0.0011
Bid:	0.0008
Ask:	0.0009
Last Trade Time:	3:47:29 PM EDT
Total Trades:	29

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

MVCO Detailed Quote

Recent MVCO News

More MVCO News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Recent MVCO News

Go Ad-Free